Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Nathan F., Azarova, Anna M., Bhatnagar, Namrata, Ross, Kenneth N., Drake, Lauren E., Frumm, Stacey, Liu, Qinsong S., Christie, Amanda L., Sanda, Takaomi, Chesler, Louis, Kung, Andrew L., Gray, Nathanael S., Stegmaier, Kimberly, George, Rani E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226718/
https://www.ncbi.nlm.nih.gov/pubmed/25228590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226718/
https://www.ncbi.nlm.nih.gov/pubmed/25228590

Ejemplares similares